User:Ahmed Zaghw

Revision as of 18:16, 14 November 2013 by Ahmed Zaghw (talk | contribs)
Jump to navigation Jump to search

Idiopathic interstitial pneumonia

Interstitial lung disease

lolo lolo2 lolo3
koko1 koko2 koko3

---

lolo lolo2 lolo3
koko1 koko2 koko3

Class I
"1. High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age who have clinical ASCVD, unless contraindicated.(Level of Evidence: A)"
"2. In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated† or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.(Level of Evidence: A)"


Cardiovascular No underlying causes
Chemical/Poisoning No underlying causes
Dental No underlying causes
Dermatologic No underlying causes
Drug Side Effect No underlying causes
Ear Nose Throat No underlying causes
Endocrine No underlying causes
Environmental No underlying causes
Gastroenterologic No underlying causes
Genetic No underlying causes
Hematologic No underlying causes
Iatrogenic No underlying causes
Infectious Disease No underlying causes
Musculoskeletal/Orthopedic No underlying causes
Neurologic No underlying causes
Nutritional/Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic No underlying causes
Ophthalmologic No underlying causes
Overdose/Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal/Electrolyte No underlying causes
Rheumatology/Immunology/Allergy No underlying causes
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Miscellaneous No underlying causes
Risk category LDL goal, mg/dL Non-HDL goal, mg/dL
CHD and CHD risk equivalent (10 year risk for CHD is >20%) < 100 < 130
Multiple (2+) risk factor (10 year risk for CHD is <20%) < 130 < 160
0-1 risk factors < 160 < 190

ATP III LDL cholesterol and Non-HDL cholesterol goals [1]


Class I
"1. Individuals with LDL–C ≥190 mg/dL or triglycerides ≥500 mg/dL should be evaluated for secondary causes of hyperlipidemia.(Level of Evidence: B)"
"2. Adults ≥21 years of age with primary LDL–C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required):
  • Use high-intensity statin therapy unless contraindicated.
  • For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity.(Level of Evidence: B)"

References

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)". JAMA. 285 (19): 2486–97. PMID 11368702.